Eli Lilly Reports P-III Trial (SURMOUNT-3) Results of Tirzepatide for Obesity or Overweight
Shots:
- The P-III trial evaluating tirzepatide in 806 patients across the US, incl. Puerto Rico, Argentina & Brazil to a lead-in period with intensive lifestyle intervention
- The trial met co-1EPs for the efficacy estimand and treatment-regimen estimand & showed superiority to PBO during the 72wk. treatment period. In both estimand, percent change in body weight (-18.4% vs 2.5%) and (-21.1% vs 3.3%); ≥5% weight reduction (87.5% vs 16.5%) and (94.4% vs 10.7%) in the co-1EPs
- In the 2EPs, ≥20% weight reduction (44.7% vs 2.2%) and (54.9% vs 1.0%); patients maintained ≥80% of the body weight lost during lead-in at 72wk. (94.0% vs 43.8%) and (98.6% vs 37.8%), treatment discontinuation due to AEs (10.5% vs 2.1%). The results were published in Nature Medicine & presented at ObesityWeek 2023
Ref: Eli Lilly | Image: Eli Lilly
Related News:- Eli Lilly Reports P-III Study (VIVID-1) Results of Mirikizumab for the Treatment of Crohn's Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
